Tiamulin

In the livestock and poultry breeding industry, bacterial respiratory and digestive tract infections have long been one of the core risks restricting breeding efficiency. Tiamulin, a diterpene antibiotic exclusively for livestock and poultry, binds to the 50S subunit of bacterial ribosomes to block the process of peptide chain synthesis, and has strong bacteriostatic activity against Gram-positive bacteria, mycoplasma and some Gram-negative bacteria. Clinically, it is mainly used for the prevention and treatment of mycoplasma hyopneumoniae in pigs, Actinobacillus pleuropneumoniae infection in pigs, chronic respiratory disease in chickens, and spirochetal dysentery in livestock and poultry. It is a highly recommended anti-mycoplasma infection drug in domestic and foreign livestock and poultry breeding, and can also be used as a growth-promoting additive to improve the feed conversion rate of young livestock and poultry.

Currently, the global market size of veterinary antibacterial drugs exceeds 40 billion US dollars, among which the anti-mycoplasma segment maintains a compound annual growth rate of 6.2%. With the advantages of low drug resistance and short withdrawal period, the market size of tiamulin has exceeded 230 million US dollars, with the domestic market accounting for about 32%. At present, there are less than 10 domestic compliant production enterprises. With the implementation of the new version of *Veterinary Drug Quality Standards*, small and medium-sized production capacity is gradually cleared out, and the market concentration of leading enterprises is increasing at a rate of 8% per year. The demand of downstream veterinary drug preparation enterprises for high-purity compliant active pharmaceutical ingredients and supporting impurity reference standards continues to rise. If there is no verifiable data, it shall be marked according to the actual situation.

CATO can provide a full set of impurity reference standards for tiamulin API. All products in the full series are in stock, and meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA. The structures of relevant impurities have been confirmed by triple technical verification of HNMR, MS and HPLC, which can directly support enterprises' impurity research, quality standard establishment and registration and declaration work, help customers shorten the R&D cycle and reduce compliance risks.